SAN FRANCISCO, Sept. 15, 2022 (GLOBE NEWSWIRE) — ProSomnus, a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), announced today that the ProSomnus EVOTM The sleep and snoring device is now reimbursable by the statutory health insurance companies in Germany.
An alternative to older oral and CPAP machines, the ProSomnus EVO can lead to more effective treatment and better patient compliance. It repositions and stabilizes the jaw during sleep and improves airflow through a patient’s throat. The ProSomnus EVO consists of upper and lower jaw aligners for orthodontic treatment, which are precision manufactured with twin pins and digitally milled patient-specifically. Prescribed advancements can be achieved by removing the current maxillary or mandibular arch and inserting the next arch in the mandibular advance series.
“The German reimbursement update provides an excellent opportunity to scale treatment to thousands of patients with OSA,” said Gregory Vogel, VP International Business at ProSomnus. “ProSomnus’ precedent for providing world-class products and services in North America paves the way for growth and expansion in Europe. We look forward to continuing our investment in the people and resources needed to support our clinical providers.”
“The reimbursement validation helps establish ProSomnus precision intraoral devices as an effective, patient-preferred and economically viable treatment option for healthcare providers in Germany and the estimated 26 million people in the country who suffer from OSA,” said Len Liptak, Co-Founder and Chief Executive Officer of ProSomnus.
ProSomnus participates in five European conferences on sleep medicine
ProSomnus will also be exhibiting research on its OAT devices at five meetings in Europe in 2022. The company will provide updates on the First-Line Obstructive Sleep Apnea Treatment (FLOSAT) study and exhibit research on its OAT devices. ProSomnus will…
[ad_2]
Source story
